StreetInsider.com News Articles

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

CAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced its participation in a key opinion leader (KOL) webinar hosted by Roth Capital Partners titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)." The webinar will bring together leading experts to discuss the current treatment landscape

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

Mon, 06 Jul 2026 08:45:00 -0400

Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward

NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial

Mon, 29 Jun 2026 09:30:37 -0400

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis (ALS) met its primary efficacy endpoint, showing a statistically significant reduction in TDP-43 levels compared to placebo.

At Day 180, PrimeC produced a statistically significant reduction in TDP-43 versus placebo (p=0.0421). The effect continued over 18 months, with continuously treated participants maintaining lower TDP-43 levels than the placebo group at Day 540 (p<0.001). TDP-43 is present in more than 97% of ALS cases.

The company claims this is the first randomized, double-blind, placebo-controlled trial to demonstrate a treatment-associated reduction in TDP-43 in people living

NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial

Mon, 29 Jun 2026 09:30:37 -0400

The company claims this is the first randomized, double-blind, placebo-controlled trial to demonstrate a treatment-associated reduction in TDP-43 in people living

NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial

Mon, 29 Jun 2026 09:30:37 -0400

The company claims this is the first randomized, double-blind, placebo-controlled trial to demonstrate a treatment-associated reduction in TDP-43 in people living

NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial

Mon, 29 Jun 2026 09:30:37 -0400

The company claims this is the first randomized, double-blind, placebo-controlled trial to demonstrate a treatment-associated reduction in TDP-43 in people living

NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial

Mon, 29 Jun 2026 09:30:37 -0400

The company claims this is the first randomized, double-blind, placebo-controlled trial to demonstrate a treatment-associated reduction in TDP-43 in people living

NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial

Mon, 29 Jun 2026 09:30:37 -0400

The company claims this is the first randomized, double-blind, placebo-controlled trial to demonstrate a treatment-associated reduction in TDP-43 in people living

NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial

Mon, 29 Jun 2026 09:30:37 -0400

The company claims this is the first randomized, double-blind, placebo-controlled trial to demonstrate a treatment-associated reduction in TDP-43 in people living

NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial

Mon, 29 Jun 2026 09:30:37 -0400

The company claims this is the first randomized, double-blind, placebo-controlled trial to demonstrate a treatment-associated reduction in TDP-43 in people living

NeuroSense ALS drug meets Phase 2b primary endpoint in TDP-43 trial

Mon, 29 Jun 2026 09:30:37 -0400

The company claims this is the first randomized, double-blind, placebo-controlled trial to demonstrate a treatment-associated reduction in TDP-43 in people living